These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
169 related articles for article (PubMed ID: 20586686)
41. Practical guidance for prescribing ziprasidone in acute manic or mixed episodes of bipolar I disorder. Cañas F; Correll CU; Fagiolini A; Larmo I; Levy P; Papageorgiou G; Rossi A; Zink M; Montes JM Expert Opin Pharmacother; 2011 Oct; 12(14):2245-63. PubMed ID: 21801083 [TBL] [Abstract][Full Text] [Related]
42. Ziprasidone for the treatment of acute manic or mixed episodes associated with bipolar disorder. Warrington L; Lombardo I; Loebel A; Ice K CNS Drugs; 2007; 21(10):835-49. PubMed ID: 17850172 [TBL] [Abstract][Full Text] [Related]
43. Efficacy, long-term safety, and tolerability of ziprasidone in children and adolescents with bipolar disorder. Findling RL; Cavuş I; Pappadopulos E; Vanderburg DG; Schwartz JH; Gundapaneni BK; DelBello MP J Child Adolesc Psychopharmacol; 2013 Oct; 23(8):545-57. PubMed ID: 24111980 [TBL] [Abstract][Full Text] [Related]
44. Ziprasidone in the treatment of affective disorders: a review. Rosa AR; Franco C; Torrent C; Comes M; Cruz N; Horga G; Benabarre A; Vieta E CNS Neurosci Ther; 2008; 14(4):278-86. PubMed ID: 19040553 [TBL] [Abstract][Full Text] [Related]
45. Ziprasidone in bipolar disorder. Versiani M Expert Opin Pharmacother; 2006 Jun; 7(9):1221-8. PubMed ID: 16732708 [TBL] [Abstract][Full Text] [Related]
46. Efficacy of aripiprazole versus placebo as adjuncts to lithium or valproate in relapse prevention of manic or mixed episodes in bipolar I patients stratified by index manic or mixed episode. Yatham LN; Fountoulakis KN; Rahman Z; Ammerman D; Fyans P; Marler SV; Baker RA; Carlson BX J Affect Disord; 2013 May; 147(1-3):365-72. PubMed ID: 23290791 [TBL] [Abstract][Full Text] [Related]
47. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Popovic D; Reinares M; Goikolea JM; Bonnin CM; Gonzalez-Pinto A; Vieta E Eur Neuropsychopharmacol; 2012 May; 22(5):339-46. PubMed ID: 22000157 [TBL] [Abstract][Full Text] [Related]
48. Ziprasidone for schizophrenia and bipolar disorder: a review of the clinical trials. Greenberg WM; Citrome L CNS Drug Rev; 2007; 13(2):137-77. PubMed ID: 17627670 [TBL] [Abstract][Full Text] [Related]
49. Risk for adverse events and discontinuation due to adverse events of ziprasidone monotherapy relative to placebo in the acute treatment of bipolar depression, mania, and schizophrenia. Gao K; Pappadopulos E; Karayal ON; Kolluri S; Calabrese JR J Clin Psychopharmacol; 2013 Jun; 33(3):425-31. PubMed ID: 23609405 [TBL] [Abstract][Full Text] [Related]
50. Estimation of resource utilisation difference between lithium and valproate treatment groups from the VALID study. Li SC; Aggarwal SK J Med Econ; 2011; 14(3):350-6. PubMed ID: 21542675 [TBL] [Abstract][Full Text] [Related]
51. Long-term safety and efficacy of ziprasidone in subpopulations of patients with bipolar mania. Keck PE; Versiani M; Warrington L; Loebel AD; Horne RL J Clin Psychiatry; 2009 Jun; 70(6):844-51. PubMed ID: 19573482 [TBL] [Abstract][Full Text] [Related]
52. A 6 week randomized double-blind placebo-controlled trial of ziprasidone for the acute depressive mixed state. Patkar A; Gilmer W; Pae CU; Vöhringer PA; Ziffra M; Pirok E; Mulligan M; Filkowski MM; Whitham EA; Holtzman NS; Thommi SB; Logvinenko T; Loebel A; Masand P; Ghaemi SN PLoS One; 2012; 7(4):e34757. PubMed ID: 22545088 [TBL] [Abstract][Full Text] [Related]
53. The role of ziprasidone in adjunctive use with lithium or valproate in maintenance treatment of bipolar disorder. Bowden CL Neuropsychiatr Dis Treat; 2011; 7():87-92. PubMed ID: 21552310 [TBL] [Abstract][Full Text] [Related]
54. The message of the survival curves: I. Composite analysis of long-term treatment studies in bipolar disorder. Frecska E; Kovacs AI; Balla P; Falussy L; Ferencz A; Varga Z Neuropsychopharmacol Hung; 2012 Sep; 14(3):155-64. PubMed ID: 22987729 [TBL] [Abstract][Full Text] [Related]
55. Randomized, Double-Blind, Placebo-Controlled Trial of Asenapine Maintenance Therapy in Adults With an Acute Manic or Mixed Episode Associated With Bipolar I Disorder. Szegedi A; Durgam S; Mackle M; Yu SY; Wu X; Mathews M; Landbloom RP Am J Psychiatry; 2018 Jan; 175(1):71-79. PubMed ID: 28946761 [TBL] [Abstract][Full Text] [Related]
56. Lurasidone in schizophrenia: new information about dosage and place in therapy. Citrome L Adv Ther; 2012 Oct; 29(10):815-25. PubMed ID: 23001538 [TBL] [Abstract][Full Text] [Related]
57. Long-term efficacy of quetiapine in combination with lithium or divalproex on mixed symptoms in bipolar I disorder. Vieta E; Suppes T; Ekholm B; Udd M; Gustafsson U J Affect Disord; 2012 Dec; 142(1-3):36-44. PubMed ID: 23062763 [TBL] [Abstract][Full Text] [Related]
58. Ziprasidone Augmentation of Escitalopram for Major Depressive Disorder: Efficacy Results From a Randomized, Double-Blind, Placebo-Controlled Study. Papakostas GI; Fava M; Baer L; Swee MB; Jaeger A; Bobo WV; Shelton RC Am J Psychiatry; 2015 Dec; 172(12):1251-8. PubMed ID: 26085041 [TBL] [Abstract][Full Text] [Related]
59. Drug safety evaluation of ziprasidone. Citrome L Expert Opin Drug Saf; 2011 May; 10(3):437-48. PubMed ID: 21332416 [TBL] [Abstract][Full Text] [Related]
60. Effects of a conventional mood stabilizer alone or in combination with second-generation antipsychotics on recurrence rate and discontinuation rate in bipolar I disorder in the maintenance phase: A systematic review and meta-analysis of randomized, placebo-controlled trials. Kishi T; Sakuma K; Okuya M; Matsuda Y; Esumi S; Hashimoto Y; Hatano M; Miyake N; Miura I; Mishima K; Iwata N Bipolar Disord; 2021 Dec; 23(8):789-800. PubMed ID: 33561884 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]